MAP3K1 and psoriasis: The association of the MAP3K1 rs96844 and ZNF816A rs9304742 polymorphisms with good response to anti-TNF medication (PASI 75 at 3 and 6 months) was subsequently confirmed in a study with 144 Spanish patients diagnosed with psoriasis (MAP3K1 rs96844-C at 3 months (p = 0.004) and at six months (p = 0.045) and ZNF816A rs9304742-T at 3 months (p = 0.02)).